Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist comprising a five-amino acid sequence. It is distinguished in research for its high selectivity for growth hormone release over other pituitary hormones, producing minimal elevation of cortisol, prolactin, or ACTH in preclinical models compared to earlier-generation growth hormone-releasing peptides (GHRPs).
Research applications include pulsatile GH secretion modelling, age-related somatotropic axis decline studies, and body composition investigations in animal models. Its favourable selectivity profile has made it a preferred research compound for isolating growth hormone axis effects from confounding hormonal variables, allowing cleaner experimental designs in endocrine research.
Studies have also characterised ipamorelin’s binding interactions with the ghrelin receptor (GHSR-1a), its dose-response relationship with pituitary GH output, and its pharmacokinetic profile. When used in combination with GHRH analogues in research protocols, ipamorelin has demonstrated synergistic amplification of GH pulse amplitude, making it a versatile tool for comprehensive somatotropic axis investigation.
Format: Lyophilised powder | Purity: ≥99% by HPLC | For Research Use Only
